Novo Nordisk EBITDA Margin 2010-2024 | NVO

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Novo Nordisk (NVO) over the last 10 years. The current EBITDA margin for Novo Nordisk as of March 31, 2024 is .
Novo Nordisk EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-03-31 $35.55B $17.47B 49.15%
2023-12-31 $33.72B $16.26B 48.22%
2023-09-30 $30.85B $14.63B 47.41%
2023-06-30 $28.44B $13.31B 46.80%
2023-03-31 $26.41B $12.35B 46.77%
2022-12-31 $25.06B $11.64B 46.44%
2022-09-30 $24.32B $11.39B 46.83%
2022-06-30 $23.81B $11.03B 46.34%
2022-03-31 $23.26B $10.77B 46.32%
2021-12-31 $22.40B $10.29B 45.93%
2021-09-30 $21.64B $9.89B 45.71%
2021-06-30 $20.85B $9.64B 46.21%
2021-03-31 $19.93B $9.26B 46.46%
2020-12-31 $19.45B $9.17B 47.17%
2020-09-30 $19.09B $9.11B 47.73%
2020-06-30 $18.74B $8.98B 47.91%
2020-03-31 $18.84B $8.96B 47.55%
2019-12-31 $18.29B $8.72B 47.65%
2019-09-30 $17.43B $8.37B 48.03%
2019-06-30 $17.25B $8.09B 46.93%
2019-03-31 $17.11B $7.98B 46.61%
2018-12-31 $17.10B $7.82B 45.76%
2018-09-30 $17.61B $7.95B 45.15%
2018-06-30 $17.49B $8.02B 45.89%
2018-03-31 $17.33B $8.06B 46.51%
2017-12-31 $16.97B $7.92B 46.68%
2017-09-30 $16.81B $7.96B 47.34%
2017-06-30 $16.73B $7.90B 47.19%
2017-03-31 $16.67B $7.80B 46.77%
2016-12-31 $16.61B $7.67B 46.19%
2016-09-30 $16.56B $7.67B 46.28%
2016-06-30 $16.43B $7.58B 46.12%
2016-03-31 $16.26B $7.51B 46.18%
2015-12-31 $16.06B $7.80B 48.56%
2015-09-30 $15.99B $7.57B 47.36%
2015-06-30 $15.95B $7.21B 45.23%
2015-03-31 $15.92B $6.88B 43.20%
2014-12-31 $15.83B $6.15B 38.84%
2014-09-30 $15.63B $5.95B 38.08%
2014-06-30 $15.31B $5.85B 38.18%
2014-03-31 $15.08B $5.75B 38.09%
2013-12-31 $14.89B $5.61B 37.68%
2013-09-30 $14.58B $5.59B 38.30%
2013-06-30 $14.27B $5.49B 38.45%
2013-03-31 $13.89B $5.31B 38.19%
2012-12-31 $13.48B $5.09B 37.77%
2012-09-30 $13.04B $4.45B 34.08%
2012-06-30 $12.80B $4.23B 33.08%
2012-03-31 $12.52B $4.07B 32.53%
2011-12-31 $12.27B $4.05B 33.02%
2011-09-30 $12.04B $4.41B 36.67%
2011-06-30 $11.85B $4.49B 37.88%
2011-03-31 $11.48B $4.34B 37.82%
2010-12-31 $11.06B $4.03B 36.43%
2010-09-30 $10.66B $4.00B 37.50%
2010-06-30 $10.24B $3.62B 35.36%
2010-03-31 $9.90B $3.35B 33.87%
2009-12-31 $9.67B $3.25B 33.62%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $632.697B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $842.050B 121.70
Johnson & Johnson (JNJ) United States $355.659B 14.13
Merck (MRK) United States $328.429B 59.76
AbbVie (ABBV) United States $303.959B 15.70
AstraZeneca (AZN) United Kingdom $243.573B 21.17
Novartis AG (NVS) Switzerland $216.133B 15.32
Pfizer (PFE) United States $157.191B 19.53
Sanofi (SNY) $118.520B 11.18
Innoviva (INVA) United States $1.003B 7.05